Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 150 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC EMA Recommends Extension of Therapeutic Indications for Epcoritamab MOST POPULAR Cancer and Climate Change: The Health Threats of Unnatural Disasters April 5, 2023 Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... July 21, 2021 EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin April 30, 2025 Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting... July 16, 2021 Load more HOT NEWS Palliative and Supportive Care for Children With Cancer: An Expert Perspective COVID-19 May Have Saved a Woman’s Life by Helping Her Discover... EMA Recommends Granting a Conditional Marketing Authorisation for Selumetinib Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally...
